Neurogene Investor Relations Material
Latest events
Study Update
Neurogene
Q1 2025
9 May, 2025
Q4 2024
24 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neurogene Inc
Access all reports
Neurogene Inc. (NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Utilizing its proprietary transgene regulation technology, known as Expression Attenuation via Construct Tuning (EXACT), Neurogene aims to address high unmet medical needs that are not effectively treated by conventional gene therapies. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Key slides for Neurogene Inc
Corporate Presentation
Neurogene Inc
Corporate Presentation
Neurogene Inc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
NGNE
Country
🇺🇸 United States